Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/41247
Registro completo de metadados
Campo DCValorIdioma
dc.creatorHerst, C. V.-
dc.creatorBurkholz, S.-
dc.creatorSidney, J.-
dc.creatorSette, A.-
dc.creatorHarris, P. E.-
dc.creatorMassey, S.-
dc.creatorBrasel, T.-
dc.creatorCunha-Neto, E.-
dc.creatorRosa, D. S.-
dc.creatorChao, W. C. H.-
dc.creatorCarback, R.-
dc.creatorHodge, T.-
dc.creatorWang, L.-
dc.creatorCiotlos, S.-
dc.creatorLloyd, P.-
dc.creatorRubsamen, R.-
dc.date.accessioned2020-05-27T13:40:02Z-
dc.date.available2020-05-27T13:40:02Z-
dc.date.issued2020-
dc.identifier.citationHERST, C. V. et al. An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design. Vaccine, [S.l.], 2020. No prelo.pt_BR
dc.identifier.urihttp://www.sciencedirect.com/science/article/pii/S0264410X20305181pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/41247-
dc.description.abstractThe 2013–2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein. The dominant response (25/26 subjects) was specific to the EBOV nucleocapsid protein (NP). It has been suggested that epitopes on the EBOV NP could form an important part of an effective T-cell vaccine for Ebola Zaire. We show that a 9-amino-acid peptide NP44-52 (YQVNNLEEI) located in a conserved region of EBOV NP provides protection against morbidity and mortality after mouse adapted EBOV challenge. A single vaccination in a C57BL/6 mouse using an adjuvanted microsphere peptide vaccine formulation containing NP44-52 is enough to confer immunity in mice. Our work suggests that a peptide vaccine based on CD8+ T-cell immunity in EBOV survivors is conceptually sound and feasible. Nucleocapsid proteins within SARS-CoV-2 contain multiple Class I epitopes with predicted HLA restrictions consistent with broad population coverage. A similar approach to a CTL vaccine design may be possible for that virus.pt_BR
dc.languageen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceVaccinept_BR
dc.subjectEbola Zaire vaccinept_BR
dc.subjectCTL vaccinept_BR
dc.subjectControllerpt_BR
dc.subjectYQVNNLEEIpt_BR
dc.subjectCOVID-19pt_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subjectFlow focusingpt_BR
dc.titleAn effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine designpt_BR
dc.typeArtigopt_BR
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.